Vimana

Vimana, the first startup out of the Duke-nference collaboration, is developing a multimodal generative AI platform to accelerate the development of precision diagnostics and therapies for neurological disorders. Vimana is building the world’s richest neuroinflammation focused data asset, linked with deep and longitudinal clinical data, expanding on nference’s nSights platform with proprietary multi-omics brain tissue biobank data from Duke.
Vimana's multimodal A.I. platform is designed to develop software solutions that could speed up the creation of precision diagnostics, surgical interventions, and novel treatments. The company's product development plan targets large markets with significant unmet needs in diagnostics, therapeutics, and care pathways, such as neurodegenerative diseases like multiple sclerosis, Parkinson's Disease, Alzheimer's, and ALS, as well as brain tumors and neurosurgery. Vimana is directed and advised by leaders in healthcare A.I. and neuro-oncology.